

OncoTherapy Science, Inc.

March 22, 2016

The completion of the cancer peptide vaccine 'OTSGC-A24'
phase I/II clinical study for gastric cancer

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, "OncoTherapy") announces that investigator-initiated Phase I/II clinical study of the cancer peptide vaccine 'OTSGC-A24' for gastric cancer performed in Singapore, Korea and Japan have been completed with favorable results on safety and immune reactivity, which are main objectives for this study.

This clinical study has been conducted as an investigator-initiated trial to evaluate the safety and immune reactivity of OTSGC-A24, cancer peptide vaccine originated from OncoTherapy, for patients with refractory gastric cancer.

OncoTherapy will promote the development of cancer immune therapy including peptide vaccine based on the results obtained from this study.

OTSGC-A24 is the cocktail vaccine product which contains multiple peptide vaccines targeting the tumor-specific antigens, highly expressed in gastric cancer cells. Each peptide vaccine contained in this cocktail is expected to induce cytotoxic T lymphocyte.